Table 1 Patient characteristics

From: A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer

Total no. of patients

55

 No. of evaluable patients

49

Median age in year

54

 Range

25–81

Male/Female

33/22

ECOG performance status

 0

3

 1

41

 2

11

Previous treatment

 None

43

 Operation

12

Palliative/curative

4/8

 Chemotherapy

4

IP/adjuvant

2/2